COVID-19 News & Media

News and Information on COVID-19

Latest COVID-19 News

Oct 19 2020

LabCorp Launches Quantitative Antibody Test to Assess Effectiveness of COVID-19 Vaccines in Clinical Trials

Quantitative Test is Used to Assess Immune Response and to Support Other Scientific Research

BURLINGTON, N.C.-- LabCorp (NYSE: LH), a leading global life sciences company that is focused on advancing health and guiding patient care, today announced a test that provides a quantitative measurement of an individual’s SARS-CoV-2 IgG antibodies. LabCorp’s Cov2Quant™ IgG test, which is available only for use in clinical trials and research, was developed to specifically detect and quantify antibodies to SARS-CoV-2, the virus that causes COVID-19. The level of antibodies is an important indicator of the strength of a person’s immune response, which can help determine the effectiveness of vaccines and therapies. Other COVID-19 antibody tests available in the market are qualitative and detect the presence of antibodies, but do not provide information on the individual’s antibody levels.

Read more »


Previous News Releases and Media Statements

Testing Overview

17.3M

Molecular 
tests performed

210K

Molecular test 
capacity per day**

3M

Antibody
tests performed

300K

Antibody test 
capacity per day**

Tests Offered with No Upfront Costs
by LabCorp*

LabCorp's COVID-19 PCR Testing
Average Time to Result+

1 Day

Week ending October 11, 2020

Get COVID-19 Updates from LabCorp

Sign up to receive COVID-19 testing updates and other relevant messages from LabCorp.

Scroll back to top of page